(329 days)
No
The device description explicitly states, "The AngioCloud Service does not use any artificial intelligence or machine learning functionality and the main segmentation algorithm is based on level-set methods."
No.
The device is used for visualization and measurement of cerebral blood vessels for preoperational planning, not for direct treatment or diagnosis. It serves as a tool to aid the healthcare provider's judgment and analysis, rather than providing therapy itself.
Yes
The device enables visualization and measurement of cerebral blood vessels for preoperational planning and sizing for neurovascular interventions and surgery, which are activities directly related to diagnosing or aiding in the diagnosis of patient conditions.
Yes
The device is described as a "standalone web-application" that runs on standard computers and mobile browsers, processing DICOM data. There is no mention of accompanying hardware components required for its primary function.
Based on the provided information, the AngioCloud Service is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This typically involves tests performed on blood, urine, tissue, etc.
- AngioCloud Service Functionality: The AngioCloud Service processes medical images (3D-RA DICOM datasets) of cerebral blood vessels. It provides tools for visualization, measurement, and planning based on these images. It does not analyze biological specimens.
- Intended Use: The intended use is for "visualization and measurement of cerebral blood vessels for preoperational planning and sizing for neurovascular interventions and surgery." This is a medical imaging analysis and planning tool, not a diagnostic test performed on a biological sample.
Therefore, the AngioCloud Service falls under the category of medical imaging software or a medical device used for surgical planning, rather than an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The AngioCloud Service enables visualization and measurement of cerebral blood vessels for preoperational planning and sizing for neurovascular interventions and surgery.
General functionalities are provided such as:
- Segmentation of neurovascular structures
- · Centerline calculation
- · Visualization of 3D vascular images
- · Measurement and annotation tools
- · Case sharing and reporting tools
Information provided by the software is not intended in any way to eliminate, replace, or substitute for, in whole or in part, the healthcare provider's judgment and analysis of the patient's condition.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
The AngioCloud Service is a standalone web-application which intends to receive a 3D rotational angiography (3D-RA) DICOM dataset and provide interactive views to physicians for the visualization and measurement of cerebral vasculatures during preoperational planning. Physicians can query a 3D-RA dataset directly via the AngioCloud Service provided that they have an internet browser with access to the internet. General functionalities are provided such as:
- Segmentation of neurovascular structures ●
- . Centerline calculation
- Visualization of 3D vascular images
- . Measurement and annotation tools
- Case sharing and reporting tools
The AngioCloud Service runs as a web application on a standard Windows or Mac OS X based computer and can also be accessed on mobile web browsers, but with limited software functionalities enabled. The AngioCloud Service does not use any artificial intelligence or machine learning functionality and the main segmentation algorithm is based on level-set methods. The Visualization Toolkit (VTK) and Vascular Model Toolkit (VMTK) serve as important software libraries that the underlying algorithm of AngioCloud Service leverages for a number of computational operations such as 3D segmentation, geometric analysis, mesh generation, and surface data analysis for image-based modeling of blood vessels. The device does not contact the patient nor does it control any life-sustaining devices. Information provided by the AngioCloud Service is not intended in any way to eliminate, replace, or substitute for, in whole or in part, the healthcare provider's judgment and analysis of the patient's condition.
The computer hardware used to access the web application must meet the following minimum requirements:
- Operating System: Windows 10 or later, Linux, Android Lollipop and later, iOS 12 or later, Mac . OS X 10.10 or later
- Memory: 4 GB RAM
- Hard Disk: At least 200 MB of free hard disk space
- Monitor 1024x768 resolution with 16-bit color ●
- Web Browser: ●
- Google Chrome: since version 83 o
- Firefox: since version 77 o
Mentions image processing
Yes
Mentions AI, DNN, or ML
No
Input Imaging Modality
3D rotational angiography (3D-RA) DICOM image data
Anatomical Site
Cerebral blood vessels / neurovascular structures
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Physicians / Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Performance testing was conducted to evaluate the AngioCloud Service segmentation module and the device met the pre-defined acceptance criteria for each performance evaluation metric. Anatomically relevant phantom models derived from clinical scans were acquired using Siemens (Artis Q with PURE) and Phillips (Allura Xper FD 20/20) Angio suites. The scans were segmented using AngioCloud Service's 'Automatic' and 'Advanced' segmentation methods and these segmentations were compared to the reference standard. The Hausdorff distance (dH) and DICE coefficient (DC) were used to evaluate segmentation performance. Both the mean DC and mean dH for each group met the acceptance criteria.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing, including verification tests, evaluated:
- DICOM images importation ●
- Case management ●
- Auto-segmentation and manual segmentation ●
- Visualization of 3D vascular images (on desktop and mobile platforms)
- Centerline calculation (on desktop and mobile platforms)
- Measurements and annotation tool (on desktop and mobile platforms) ●
- Case sharing and reporting tool .
Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices. The AngioCloud Service is considered a "moderate" level of concern, since malfunction of the software could cause a delay in generating information for preoperative planning.
Performance testing was conducted to evaluate the AngioCloud Service segmentation module and the device met the pre-defined acceptance criteria for each performance evaluation metric. Anatomically relevant phantom models derived from clinical scans were acquired using Siemens (Artis Q with PURE) and Phillips (Allura Xper FD 20/20) Angio suites. The scans were segmented using AngioCloud Service's 'Automatic' and 'Advanced' segmentation methods and these segmentations were compared to the reference standard. The Hausdorff distance (dH) and DICE coefficient (DC) were used to evaluate segmentation performance. Both the mean DC and mean dH for each group met the acceptance criteria.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Hausdorff distance (dH), DICE coefficient (DC). Both the mean DC and mean dH for each group met the acceptance criteria.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
AngioCloud, LLC % Bahram Parvinian Founder & Principal Consultant Lighthouse Regulatory Consulting Group, LLC 3 Harrowgate CT POTOMAC MD 20854
April 28, 2022
Re: K211713
Trade/Device Name: AngioCloud Service Regulation Number: 21 CFR 892.2050 Regulation Name: Medical image management and processing system Regulatory Class: Class II Product Code: LLZ Dated: March 14, 2022 Received: March 23, 2022
Dear Bahram Parvinian:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jessica Lamb, Ph.D. Assistant Director Mammography Ultrasound and Imaging Software Branch Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K211713
Device Name AngioCloud Service
Indications for Use (Describe)
The AngioCloud Service enables visualization and measurement of cerebral blood vessels for preoperational planning and sizing for neurovascular interventions and surgery.
General functionalities are provided such as:
- Segmentation of neurovascular structures
- · Centerline calculation
- · Visualization of 3D vascular images
- · Measurement and annotation tools
- · Case sharing and reporting tools
Information provided by the software is not intended in any way to eliminate, replace, or substitute for, in whole or in part, the healthcare provider's judgment and analysis of the patient's condition.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
K211713
Date Prepared
April 25, 2022
Submission Number K211713
510(k) Submitter
AngioCloud, LLC 1 Glenlake Parkway, Suite 200 Atlanta, GA 30328
| Official Contact: | James Lewis |
|---|---|
| Telephone: | +1-803-269-1545 |
| Email: | james@angiocloud.com) |
Primary Contact
Bahram Parvinian M.S., Principal Consultant Lighthouse Regulatory Consulting Group LLC Telephone: +1-301-938-7669 Email: bahram(@lighthouseregulatory.com
LLZ
Class II
Device Information
| Trade/Proprietary Name | AngioCloud Service |
|---|---|
| Common Device Name | System, Image processing, Radiological |
| Classification Name | Medical Image Management and Processing System |
21 CFR 892.2050
Regulation Number Product Code Classification
Predicate Device
EndoVantage SurgicalPreview™ (K171534)
Reference Device
Visible Patient Suite (K212896)
Device Description
The AngioCloud Service is a standalone web-application which intends to receive a 3D rotational angiography (3D-RA) DICOM dataset and provide interactive views to physicians for the visualization and measurement of cerebral vasculatures during preoperational planning. Physicians can query a 3D-RA dataset directly via the AngioCloud Service provided that they have an internet browser with access to the internet. General functionalities are provided such as:
4
- Segmentation of neurovascular structures ●
- . Centerline calculation
- Visualization of 3D vascular images
- . Measurement and annotation tools
- Case sharing and reporting tools
The AngioCloud Service runs as a web application on a standard Windows or Mac OS X based computer and can also be accessed on mobile web browsers, but with limited software functionalities enabled. The AngioCloud Service does not use any artificial intelligence or machine learning functionality and the main segmentation algorithm is based on level-set methods. The Visualization Toolkit (VTK) and Vascular Model Toolkit (VMTK) serve as important software libraries that the underlying algorithm of AngioCloud Service leverages for a number of computational operations such as 3D segmentation, geometric analysis, mesh generation, and surface data analysis for image-based modeling of blood vessels. The device does not contact the patient nor does it control any life-sustaining devices. Information provided by the AngioCloud Service is not intended in any way to eliminate, replace, or substitute for, in whole or in part, the healthcare provider's judgment and analysis of the patient's condition.
The computer hardware used to access the web application must meet the following minimum requirements:
- Operating System: Windows 10 or later, Linux, Android Lollipop and later, iOS 12 or later, Mac . OS X 10.10 or later
- Memory: 4 GB RAM
- Hard Disk: At least 200 MB of free hard disk space
- Monitor 1024x768 resolution with 16-bit color ●
- Web Browser: ●
- Google Chrome: since version 83 o
- Firefox: since version 77 o
Indications for Use
The AngioCloud Service enables visualization and measurement of cerebral blood vessels for preoperational planning and sizing for neurovascular interventions and surgery.
General functionalities are provided such as:
- Segmentation of neurovascular structures
- Centerline calculation ●
- . Visualization of 3D vascular images
- Measurement and annotation tools .
- Case sharing and reporting tools ●
Information provided by the software is not intended in any way to eliminate, replace, or substitute for, in whole or in part, the healthcare provider's judgment and analysis of the patient's condition.
Comparison of Technological Characteristics with the Predicate Device
The subject device has the same intended use and similar indications for use and technological characteristics (e.g. software for visualization and measurement of cerebral blood vessels for
5
preoperative planning) to the predicate device (K171534). The differences in technological characteristics between the subject and predicate devices are explained below. AngioCloud does not believe that these differences raise different questions of safety and effectiveness.
- In the predicate device, the input data is a DICOM dataset from all CT scanner vendors, whereas . the subject device only accepts volumetric DICOM data acquired by 3D-RA scanners from the Phillips and Siemens X-ray systems. These technological characteristics have undergone testing to ensure the device is substantially equivalent to the predicate.
- In the predicate device, the patient-specific anatomical models that are output by the ● SurgicalPreview™ software are generated by operators who are in-house EndoVantage employees and allow the end-user clinician to review and comment, whereas the subject device generates anatomical models by the Segmentation Engine. The end-user clinician of the subject device can manually adjust the segmentation threshold or choose an 'Auto' option where an estimated segmentation threshold is adopted for segmentation. These technological characteristics have undergone testing to ensure the device is substantially equivalent to the predicate.
- The predicate device is not indicated for use on a mobile platform whereas the AngioCloud Service ● is compatible with and can be accessed through a mobile device web browser. Mobile platform access allows for the visualization and sharing of 3D vascular images through the 3D Viewer and for quick ruler and centerline measurements. All other functionalities of the AngioCloud Service are disabled during use on a mobile web browser. This technological characteristic has undergone testing and has been considered as part of the risk assessment to ensure the device is substantially equivalent to the predicate.
- The predicate device is not indicated for case sharing, whereas the AngioCloud Service allows for de-identified cases to be shared between authorized users. Case sharing features have been evaluated through the risk assessment and software verification testing to ensure that this technological characteristic is substantially equivalent to the predicate.
The predicate device has the following additional functionalities which AngioCloud Service does not offer:
- Volume measurements (e.g. aneurysmal volume)
- . Line measurements on aneurysm (e.g. aneurysmal neck width and dome height)
- Import patient data via study creation list ●
- 2D cross-sectional slice review of vessel (e.g. diameter measurement tool) ●
- Deployment video tool
- Deployment simulation report .
AngioCloud believes that the AngioCloud Service's indications for use and technological characteristics are substantially equivalent to the legally marketed predicate device (K171534) based on the information summarized in Table 1 - Substantial Equivalence Summary.
6
| Table 1 - Substantial Equivalence Summary | ||
|---|---|---|
| Subject Device | Primary Predicate Device | |
| Trade Name | AngioCloud Service | SurgicalPreview™ |
| Manufacturer | AngioCloud Inc | Endovantage |
| 510(k) Number | K211713 | K171534 |
| Class | II | II |
| Device Classification | ||
| Name | System, Image processing, | |
| Radiological | Software For Visualization of | |
| Vascular Anatomy And | ||
| Intravascular Devices | ||
| Regulation Number | 892.2050 | 892.2050 |
| Product Code | LLZ | PZO |
| Indications for Use | The AngioCloud Service enables | |
| visualization and measurement of | ||
| cerebral blood vessels for | ||
| preoperational planning and sizing | ||
| for neurovascular interventions and | ||
| surgery. |
General functionalities are provided
such as:
Segmentation of
neurovascular structuresCenterline calculationVisualization of 3D
vascular imagesMeasurement and
annotation toolsCase sharing and reporting
tools
Information provided by the
software is not intended in any way
to eliminate, replace, or substitute
for, in whole or in part, the
healthcare provider's judgment and
analysis of the patient's condition. | SurgicalPreview™ enables
visualization and measurement of
vessels for preoperational planning
and sizing for neurovascular
interventions and surgery.
SurgicalPreview™ also allows for
the ability to computationally model
the placement and deployment of
neurointerventional devices.
General functionalities are provided
such as:
Segmentation of
neurovascular structuresAutomatic centerline
detectionVisualization of CT scan
images for 2D review and
3D reconstructionMeasurement and
annotation toolsReporting tools
Information provided by the
software is not intended in any way
to eliminate, replace, or substitute
for, in whole or in part, the
healthcare provider's judgment and
analysis of the patient's condition. |
| Interface to Image
Sources | 3D rotational angiography (3D-RA)
DICOM image data | CT DICOM image data |
| Import of Patient Data | Manual through keyboard/mouse,
automatic import with image file | Manual through keyboard/mouse,
automatic import with image file,
study creation list |
| List Image
Functionality | Deleting, anonymizing, search | Same |
| Image Processing | Segmentation by Segmentation
Engine with end-user clinical
review and comment. | Segmentation by EndoVantage
operator with end-user clinical
review and comment. |
| | Subject Device | Primary Predicate Device |
| | End-user can manually adjust the
segmentation threshold by choosing
the 'Advanced' option or apply an
estimated segmentation threshold
by choosing the 'Automatic' option. | |
| 3D Assessment | Linear (length and diameter)
measurements, centerline
measurement | Linear (length and diameter)
measurements, volume
measurements. |
| Image and 3D Display | Orthogonal, color volume
rendering, and 3D visual view of
centerline | Orthogonal, color volume
rendering, 2D slice review, active
presets, 3D view of assemblies of
devices |
| DICOM Support | Compatible with 3D-RA DICOM
datasets, storage SCP, import
DICOM files, DICOM compliance
for 3D-RA CT, storage SCU,
query/retrieve SCU | Compatible with all scanner vendor
DICOM datasets, storage SCP,
import DICOM files, DICOM
compliance for CT and enhanced
CT, import from DICOMDIR,
storage SCU, query/retrieve SCU |
| Computer OS
Compatibility | MS Windows and Mac OS | Same |
| Mobile OS
Compatibility | Yes, mobile browser compatible
with limited functionalities | No |
| Data Interchange /
Transfer Method | Secure Internet File Server | Same |
| Output File Format | Web browser via WebGL | Same |
| Preoperational
Planning | Yes | Same |
| Patient Contact | No | Same |
| Human Intervention for
Interpretation of
Images | Yes | Same |
Table 1 - Substantial Equivalence Summary
7
Performance Data
AngioCloud Service is designed in conformance with the following FDA recognized consensus standards:
- NEMA PS 3.1 3.20 (2016) Digital Imaging and Communications in Medicine (DICOM) Set ●
- ISO 14971:2019 Medical Devices Application of Risk Management to Medical Devices ●
- IEC 62304:2006/AMD 1:2015 - Medical Device Software - Software Life-Cycle Processes
- ISO/IEC 10918-1 First Edition 1994-02-15 Information technology Digital compression and ● coding of continuous-tone still images: Requirements and guidelines
- . ANSI/AAMI/IEC 62366-1:2015 Medical devices - Part 1: Application of usability engineering to medical devices
All specifications of the AngioCloud Service are verified by a number of tests before release. Nonclinical testing, including verification tests, evaluated:
- DICOM images importation ●
- Case management ●
- Auto-segmentation and manual segmentation ●
8
- Visualization of 3D vascular images (on desktop and mobile platforms)
- Centerline calculation (on desktop and mobile platforms)
- Measurements and annotation tool (on desktop and mobile platforms) ●
- Case sharing and reporting tool .
Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices. The AngioCloud Service is considered a "moderate" level of concern, since malfunction of the software could cause a delay in generating information for preoperative planning.
Performance testing was conducted to evaluate the AngioCloud Service segmentation module and the device met the pre-defined acceptance criteria for each performance evaluation metric. Anatomically relevant phantom models derived from clinical scans were acquired using Siemens (Artis Q with PURE) and Phillips (Allura Xper FD 20/20) Angio suites. The scans were segmented using AngioCloud Service's 'Automatic' and 'Advanced' segmentation methods and these segmentations were compared to the reference standard. The Hausdorff distance (dH) and DICE coefficient (DC) were used to evaluate segmentation performance. Both the mean DC and mean dH for each group met the acceptance criteria.
AngioCloud believes that the aforementioned non-clinical testing demonstrates that the AngioCloud Service is designed in such a way that, when used in accordance with its indications for use and labeling, the safety and effectiveness, as well as the performance characteristics of the subject device are substantially equivalent to the predicate device.
Substantial Equivalence Conclusion
AngioCloud Service has the same intended use and performance characteristics as the predicate device. Based on the performance data and software verification testing, it can be concluded that the differences in technological characteristics between the AngioCloud Service and the predicate device do not raise different questions of safety and effectiveness. The indications for use, technological characteristics, and performance characteristics for the AngioCloud Service are assessed to be substantially equivalent to those of the predicate device.